Advertisement
Dr. Rodgerson's lecture, entitled, "Stem Cells & Regenerative Medicine:Past, Present & Future," will address the evolving nature of stem cellresearch and applications as well as NeoStem's proprietary Very SmallEmbryonic Like Stem Cells (VSELs) technology and its potential role in themarket.
Advertisement
Dr. Rodgerson has published more than 150 articles in medical andscientific literature and is the holder of several patents. He is an inventorof the proprietary process that serves as the basis for NeoStem's platformstem cell collection business and was the founder of NeoStem's predecessorcompany. He has been a consultant to many institutions and corporations,including NASA, National Bureau of Standards, Hewlett Packard, and BeckmanInstruments. Prior to founding NeoStem, Dr. Rodgerson founded StemCyte, Inc.,an umbilical cord blood banking company, where he served as Chief OperatingOfficer and Senior Vice President until 2002. He is also Professor Emeritusof Pathology and Laboratory Medicine at the UCLA School of Medicine.
About NeoStem, Inc.
NeoStem is managing a growing nationwide network of adult stem cellcollection centers, enabling people to donate and store their own (autologous)stem cells when they are young and healthy for their personal use in times offuture medical need. The Company has also recently entered the research anddevelopment and therapeutic arenas, through the acquisition of a worldwideexclusive license to an early-stage technology to identify and isolate rarestem cells from adult human bone marrow, called VSELs (very small embryonic-like stem cells), which have been shown to have several physicalcharacteristics that are generally found in embryonic stem cells.
Forward-Looking Statements
Certain statements in this press release constitute "forward-lookingstatements" within the meaning of the Private Securities Litigation Reform Actof 1995, including statements concerning the ability of NeoStem, Inc. ("theCompany") to develop the adult stem cell business, to develop the VSELtechnology, the future of regenerative medicine and the role of adult stemcells and VSELs in that future, the future use of adult stem cells and VSELsas a treatment option and the potential revenue growth of the Company'sbusiness. Such forward-looking statements involve known and unknown risks,uncertainties and other factors, which may cause the actual results,performance or achievements of the Company, or industry results, to bematerially different from any future results, performance, or achievementsexpressed or implied by such forward-looking statements. The Company's abilityto enter the adult stem cell arena, its success in such arena and futureoperating results are dependent upon many factors, including but not limitedto (i) the Company's ability to obtain sufficient capital or a strategicbusiness arrangements to fund its expansion plans; (ii) the Company's abilityto build the management and human resources and infrastructure necessary tosupport the growth of its business; (iii) competitive factors and developmentsbeyond the Company's control; (iv) scientific and medical developments beyondthe Company's control; (v) the Company's inability to obtain appropriate statelicenses or any other adverse effect or limitations caused by governmentregulation of the business; (vi) whether any of the Company's current orfuture patent applications result in issued patents; and (vii) other ri
